— News, features, and commentary about cancer-related issues
Charles Bankhead, Senior Editor, MedPage Today
September 1, 2023
How to respond to a loved one who thinks prayer will cure cancer. (New York Times Magazine)
AstraZeneca has joined the legal fray in opposition to the federal government’s plans to negotiate drug prices for Medicare.
One oncology drug — ibrutinib (Imbruvica) — made the list of the first 10 drugs that Medicare wants to negotiate.
Novocure announced that adding tumor treating fields to paclitaxel did not significantly improve overall survival in advanced platinum-resistant ovarian cancer as compared with paclitaxel alone.
Genentech announced “unprecedented” improvement in disease-free survival for patients with early-stage ALK-positive non-small cell lung cancer who received adjuvant treatment with the ALK inhibitor alectinib (Alecensa).
Exercise may help relieve sexual dysfunction associated with prostate cancer treatment. (Edith Cowan University)
Why breast cancer survivors don’t take their medication and what can be done about it. (University of Colorado Boulder)
A widely used drug to treat hot flashes in breast cancer survivors turned out to be no better than placebo. (Baylor University)
Researchers who reported that cancer cells harbor a wide array of microbes — bacteria, viruses, fungi — “found stuff that just wasn’t there,” according to other researchers who tried to replicate the findings. (New York Times)
Novartis plans to stop development of the anti-TGFβ antibody NIS793 for pancreatic cancer and return the rights to Xoma Corporation. (BioSpace)
The National Comprehensive Cancer Network announced plans to fund new research projects in small cell lung cancer.
Extreme dietary habits related to carbohydrate intake were associated with increased cancer-related mortality in women. (Nagoya University)
Laboratory studies of differentiation therapy have shown promise for transforming an aggressive type of musculoskeletal cancer into normal cells. (Science)